28亿元项目黄了！康泰生物终止与阿斯利康合资设立疫苗企业

Group 1 - The joint venture plan between Kangtai Biological and AstraZeneca has been terminated due to significant changes in the market environment and high risks associated with new investments in the vaccine industry [1][3] - The joint venture was initially planned to have a registered capital of 345 million RMB (approximately 50 million USD) and a total investment of around 400 million USD (about 2.76 billion RMB) [1] - The joint venture aimed to develop and commercialize innovative vaccines, including AstraZeneca's RSV and hMPV combination vaccine, in China [1] Group 2 - Kangtai Biological cited substantial downward pressure in the industry and a lack of approved vaccines for RSV and hMPV as reasons for the termination [3] - The domestic vaccine market is facing increasing homogenization due to many companies focusing on traditional products with lower market risks, leading to a slowdown in demand for children's vaccines and an underdeveloped adult vaccination market [3] - Kangtai Biological expects a significant decline in net profit for 2025, projecting a profit of 49 million to 73 million RMB, representing a year-on-year decrease of 63.80% to 75.70% [3] Group 3 - Despite the termination of the joint venture, AstraZeneca plans to invest over 100 billion RMB (approximately 15 billion USD) in China by 2030 to expand its pharmaceutical production and R&D [4]